Engineered blood clots using rapidly crosslinked red blood cells form within seconds, greatly improving toughness and adhesion while effectively stopping bleeding and enhancing tissue repair.
Researchers developed a biomaterial platform that creates artificial clots capable of halting severe hemorrhage in under 10 seconds. The technology uses a novel crosslinking agent that binds red blood cells together into a robust, tissue-adhesive network.
In pre-clinical trials on liver lacerations, the engineered clots reduced blood loss by 85% compared to standard gauze dressings and promoted faster wound healing through the controlled release of regenerative growth factors.
show all
